Resolution No. 6/19-2 

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES 

VACCINES FOR CHILDREN PROGRAM 

VACCINES TO PREVENT Haemophilus influenzae type b (Hib) 

The purpose of this resolution is to update the Recommended Vaccination Schedule and Intervals section to 

reflect the list of currently available Hib-containing vaccines that can be used to prevent Hib disease and to add a 

clarifying footnote about the timing of the booster dose that is included in the most recent recommendations. 

VFC resolution 2/13-2 is repealed and replaced by the following: 

Eligible groups 

All children 6 weeks to 18 years of age, to prevent Haemophilus influenzae type b (Hib) disease. 

Recommended Schedule and Dosage Intervals for Hib Vaccines 

The recommended schedule includes 3 or 4 doses of a Hib-containing vaccine, depending on the specific vaccine, 

as shown in Table 1. 

Table 1. Schedule for administering doses of Hib-containing vaccines 

Vaccine Brand (1) Components Primary

series

Booster dose

Monovalent vaccines 

PRP-OMP (2,3) PedvaxHIB PRP conjugated to OMP 2, 4 months 12 – 15 months 

PRP-T ActHIB PRP conjugated to tetanus 

toxoid 

2, 4, 6 months 12 – 15 months 

PRP-T Hiberix PRP conjugated to tetanus 

toxoid 2, 4, 6 months 12 – 15 months 

Combination vaccines 

DTaP-IPV/Hib Pentacel DTaP + IPV + PRP-T 2, 4, 6 months 15 – 18 months (4)

DTaP-IPV-Hib-HepB (5) Vaxelis DTaP + IPV + PRP-OMP + 

HepB 

2, 4, 6 months Not licensed (6) 

(1) Use of brand names in Table 1 is not meant to preclude the use of other licensed Hib vaccines with similar 

active components. 

(2) If a PRP-OMP vaccine is not administered as both doses in the primary series or there is uncertainty about 

which products were previously administered, a third dose of Hib conjugate vaccine is needed to complete 

the primary series. 

(3) Preferred for American Indian/Alaska Native children. 

(4) The booster dose may be administered as early as age 12 months, provided that at least 6 months have 

elapsed since the third dose.

(5) Not preferred for AI/AN children due to lack of immunogenicity data after the first dose. 
(6) DTaP-IPV-Hib-HepB is not licensed for a booster dose; any other Hib conjugate vaccine licensed for the 

booster dose can be used.

Table 2. Minimum age and intervals for Hib vaccines 

Minimum Age Minimum Intervals—Primary Series 

(Up to 12 months) 

Minimum Interval—Booster dose (12 

months and older) 

6 weeks 4 weeks 8 weeks 

The ACIP recommends Hib vaccine for all children through 5 years of age. In addition, children less than 24 

months of age who develop invasive Hib disease should be considered unvaccinated and receive Hib vaccine 

doses according to the age-appropriate schedule for unimmunized children. Vaccination or re-vaccination of 

children <24 months of age who develop invasive Hib disease should begin 4 weeks after disease. 

If Hib vaccination is not initiated by 6 months of age, use the schedule shown in Table 3. 

Table 3. Catch up Vaccination Schedule 

Age at first vaccination Primary series Booster 

7-11 months 2 doses, at least 4 weeks apart Age 12-15 months at least 8 weeks 

after the second dose* 

12-14 months 2 doses, at least 8 weeks apart N/A 

15-59 months 1 dose N/A 

* A booster dose at 12 - 15 months of age is only necessary if 2 or 3 primary doses (depending on vaccine type used) were 

administered before age 12 months. 

Table 4. Guidance for Hib Vaccination in High-Risk Groups 

High-risk group* Hib Vaccine Guidance 

Patient <12 months of age Follow routine Hib vaccination recommendations 

Patients 12 - 59 months of age 

If unimmunized or received 0 or 1 dose before age 12 months: 2 doses 2 

months apart 

If received 2 or more doses before age 12 months: 1 dose 

If completed a primary series and received a booster dose at age 12 months 

or older: no additional doses 

Patients undergoing chemotherapy 

or radiation therapy, age <59 

months† 

If routine Hib doses given 14 or more days before starting therapy: 

revaccination not required 

If dose given within 14 days of starting therapy or given during therapy: 

repeat doses starting at least 3 months following therapy completion 

Patients undergoing elective 

splenectomy, 

>15 months-18 years If unimmunized§: 1 dose prior to procedure ‡ 

Asplenic patients 

>59 months -18 years If unimmunized§: 1 dose 

HIV-infected patients 

>59 months – 18 years If unimmunized§: 1 dose 

Recipients of hematopoietic 

stem cell transplant, through 18 

years 

Regardless of Hib vaccination history: 3 doses (at least 1 month apart) 

beginning 6-12 months after transplant 
*Patients with functional or anatomic asplenia, HIV infection, immunoglobulin deficiency including 

Immunoglobulin G2 subclass deficiency, or early component complement deficiency, recipients of a 

hematopoietic stem cell transplant (HSCT), and those receiving chemotherapy for malignant neoplasms 

† Some experts suggest conducting serologic testing for these patients. 

‡Some experts suggest vaccination at least 14 days before the procedure; some experts suggest administering a 

dose prior to elective splenectomy regardless of prior vaccination history. 

§ Patients who have received a primary series and booster dose or at least 1 dose of Hib vaccine after 14 months 

of age are considered immunized

Recommended dosage 

Refer to product package inserts. 

Precautions and contraindications 

Contraindications and Precautions can be found in the package inserts available at: 

https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states

[If an ACIP recommendation regarding Hib vaccination is published within 6 months following this resolution, 

the relevant language above (except in the eligible groups sections) will be replaced with the language in the

recommendation and incorporated by reference to the publication URL.] 

Adopted and Effective: June 26, 2019 

This document can be found on the CDC website at:

https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html